Peptide Sciences BPC-157, TB-500 (Blend) 20mg | Support for Advanced Tissue Research

In the evolving landscape of regenerative biology, the BPC-157 and TB-500 Blend (20mg) by Peptide Sciences represents a sophisticated dual-pathway approach to laboratory investigation. This synergistic combination is engineered to allow researchers to study the intersection of vascular recruitment and cellular motility within biological systems. As these two peptides target distinct but complementary phases of tissue maintenance, the blend has become a focal point for studies involving musculoskeletal structural integrity and systemic physiological resilience.

Scientific Deep Dive: The Mechanistic Synergy

The biological potential of this blend lies in its “One-Two Punch” approach to tissue biology. BPC-157 (Body Protection Compound-157) is a 15-amino acid fragment originally derived from human gastric juice. Its primary mechanism in a research setting involves the upregulation of the Early Growth Response-1 (EGR-1) gene. This gene serves as a biological master switch, initiating the production of cytokines and growth factors necessary for structural repair. Furthermore, BPC-157 is heavily investigated for its role in promoting angiogenesis—the formation of new blood vessels—via the expression of Vascular Endothelial Growth Factor (VEGF). This is particularly relevant in tissues like tendons and ligaments, which naturally suffer from low blood supply.

Complementing this is TB-500, a synthetic fragment of Thymosin Beta-4. Unlike BPC-157, which focuses on the structural scaffolding and vascularity, TB-500 specializes in actin sequestration. By binding to G-actin, TB-500 maintains a pool of actin monomers that prevent the premature hardening of the cellular skeleton. This maintains cell flexibility and promotes cellular motility, allowing essential repair cells to migrate through dense extracellular matrices to reach the site of study. Together, these peptides offer a comprehensive model for investigating how the body maintains its structural and mucosal integrity.

Laboratory Usage & Reconstitution Guide

This product is provided as a lyophilized (freeze-dried) powder to ensure molecular stability during transit and storage. For laboratory research, the product must be reconstituted using a bacteriostatic medium. Researchers typically aim for a concentration that allows for precise measurement of the 20mg total peptide content. Once reconstituted, the solution should be handled with care to avoid denaturing the delicate peptide bonds. It is recommended to store the vial in a temperature-controlled environment between 2°C and 8°C. This blend is strictly intended for in vitro and laboratory animal research only; human application is not authorized.

Safety Information & Regulatory Status

Research into BPC-157 and TB-500 must be conducted with an understanding of the “Angiogenesis Paradox.” While the growth of new blood vessels is a desired outcome for studying tissue recovery, it poses a theoretical risk in the presence of undiagnosed proliferative conditions or malignancies, as tumors utilize similar pathways to thrive. Researchers should exclude models with a history of malignancy.

Regulatory Notice: As of 2023, the FDA has reclassified BPC-157 into Category 2 of the Bulk Drug Substances list, which prohibits its use in compounded medications due to a lack of long-term human safety data. Additionally, both BPC-157 and TB-500 are strictly prohibited by the World Anti-Doping Agency (WADA) and USADA. This product is not a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease.

Frequently Asked Questions